AI assistant
aTYR PHARMA INC — Director's Dealing 2022
Feb 7, 2022
34337_dirs_2022-02-07_ff54ca87-3d55-4f74-ba19-ad90e5f175d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-02-03
Reporting Person: DENYES NANCY (General Counsel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-03 | Employee Stock Option (right to buy) | $5.52 | A | 21500 | Acquired | 2032-02-03 | Common Stock (21500) | Direct |
| 2022-02-03 | Restricted Stock Units | $ | A | 10750 | Acquired | Common Stock (10750) | Direct |
Footnotes
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3: The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.